PCSK9 and myocardial infarction: The FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) study previously assessed evolocumab in a population of patients with atherosclerotic CVD (eg, a history of myocardial infarction, nonhemorrhagic stroke, and symptomatic peripheral artery disease).